Human Insulin Inhalation Powder + Injectable insulin + Insulin Glargine
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Type 1
Conditions
Diabetes Mellitus, Type 1
Trial Timeline
Aug 1, 2006 → May 1, 2008
NCT ID
NCT00356109About Human Insulin Inhalation Powder + Injectable insulin + Insulin Glargine
Human Insulin Inhalation Powder + Injectable insulin + Insulin Glargine is a phase 3 stage product being developed by Eli Lilly for Diabetes Mellitus, Type 1. The current trial status is completed. This product is registered under clinical trial identifier NCT00356109. Target conditions include Diabetes Mellitus, Type 1.
What happened to similar drugs?
20 of 20 similar drugs in Diabetes Mellitus, Type 1 were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00356109 | Phase 3 | Completed |
| NCT00127634 | Phase 3 | Completed |
Competing Products
20 competing products in Diabetes Mellitus, Type 1